3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Breast Neoplasms
256
Carcinoma, Non-Small-Cell Lung
212
Ovarian Neoplasms
134
Lung Neoplasms
107
Esophageal Neoplasms
69
Triple Negative Breast Neoplasms
64
Stomach Neoplasms
58
Fallopian Tube Neoplasms
56
Squamous Cell Carcinoma of Head and Neck
52
Neoplasm Metastasis
50
Head and Neck Neoplasms
44
Esophageal Squamous Cell Carcinoma
43
Carcinoma, Ovarian Epithelial
42
Neoplasms
36
Endometrial Neoplasms
34
Uterine Cervical Neoplasms
32
Recurrence
29
Adenocarcinoma Of Esophagus
24
Adenocarcinoma of Lung
22
Urinary Bladder Neoplasms
21
Melanoma
20
Carcinoma, Squamous Cell
19
Carcinoma
18
Small Cell Lung Carcinoma
17
Prostatic Neoplasms
15
Breast Neoplasms, Male
15
Adenocarcinoma, Bronchiolo-Alveolar
13
Peritoneal Neoplasms
12
Inflammatory Breast Neoplasms
12
Testicular Neoplasms
10
Interventions
Paclitaxel
2
liposomal doxorubicin
1
Tocotrienols
1
Platinum Compounds
1
EP-100 membrane-disrupting peptide
1
Carboplatin
1
Bevacizumab
1
AC 7700
1
1-dodecylpyridoxal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Ovarian Cancer Recurrent
×
Paclitaxel
×
Clear all
NCT01332656
2015-12-21
OPSALIN
Sanofi
Phase 2
Completed
154 enrolled
NCT01485848
2014-06-10
ESP2011-002
Esperance Pharmaceuticals Inc
Phase 2
Completed
49 enrolled